Eli Lilly (LLY): FY24 Q4 earnings call, Feb 6, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Feb 6, 2025 earnings call (FY24 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
22 matches for “Phase 3”; 5 quoted, at least 25 words apart.
…as our recently launched products gained momentum. Last year, we announced positive Phase III results for imlunestrant, insulin efsitora alfa and 3 additional tirzepatide trials.…
…metastatic breast cancer and tirzepatide for heart failure. We also announced positive Phase III results in the SURMOUNT-5 study, where Zepbound demonstrated a 47% greater…
…in our early and late-stage portfolio. In total, we started 8 new Phase III programs in 2024 and advanced several new assets into the clinic.…
…and late-stage activities. As Dan will share later, we started 8 new Phase III programs in 2024 and anticipate that investment in those programs will…
…and the FDA has granted the submission a priority review. In our Phase III portfolio, we initiated a new program for Orforglipron in obstructive sleep…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-02-06:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-02-06:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP